Details

Autor(en) / Beteiligte

• Ilié, Marius
• Mazières, Julien
• Chamorey, Emmanuel
• Heeke, Simon
• Thamphya, Brice
• Boutros, Jacques
• Cadranel, Jacques
• Poudenx, Michel
• Barlesi, Fabrice
• Thariat, Juliette
• Clément-Duchêne, Christelle
• Hofman, Véronique
• Marquette, Charles-Hugo
• Hofman, Paul
• Israel-Biet, Dominique
• Moro-Sibilot, Denis
• Lantuejoul, Sylvie
• Stephanov, Olivier
• Mendozat, Christophe
• Zaidi, Manel
• Coulouvrat, Sandra
• Col, Edwige
• Chanez, Pascal
• Greillier, Laurent
• Mascaux, Céline
• Jourdan, Sandrine
• Roger, Aurélie
• Biemar, Julie
• Randriamampionona, Rondro
• Chabot, François
• Clement-Duchene, Christelle
• Lacomme, Stéphanie
• Lomazzi, Sandra
• Laurent, Carine
• Bulsei, Xavier
• Bischoff, Laura
• Rakotonirina, Raymond
• Layouni, Mehdi
• Deslee, Gaëtan
• Mal, Hervé
• Vergnon, Jean-Michel
• Cuvelier, Antoine
• Bourdin, Arnaud
• Roche, Nicolas
• Bonniaud, Philippe
• Scherpereel, Arnaud
• Mornex, Jean François
• Leroy, Sylvie
• Marquette, Charles Hugo
• Mazzette, Andrea
• Padovani, Bernard
• Fayada, Julien
• Long-Mira, Elodie
• Lassalle, Sandra
• Martinez, Estelle
• Habault, Marine
• Bonnard, Mélanie
• Moutarde, Julie
• Yatimi, Rachida
• Gazoppi, Loïc
• Lpce, Tumorothèque
• Fontaine, Maureen
• Guillemart, Ariane
• Butori, Catherine
• Otto, Josiane
• Hebert, Christophe
• Botchiellini, Delphine
• Boudouf, Soukaina
• Menier, Margaux
• Bellentani, Sophie
• Fournier, Elodie
• Gervais, Radj
• Hamond, Karim
• Marchand-Adam, Sylvain
• Plantier, Laurent
• Fajolle, Gaelle
• Rayez, Mélanie
• Fallet, Vincent
• Wislez, Marie
• Antoine, Martine
• Chaabane, Nouha
• Ruppert, Anne Marie
• Pontdeme, Gwenaëlle
• Mathiot, Nathalie
• Ribert, Tamazouzt
• Guibert, Nicolas
• Bigay-Game, Laurence
• Hermant, Christophe
• Plat, Gavin
• Evrard, Solène
• Gouin, Sandrine
• Coulomb, Christelle
• Pradine, Anne
• Lambert, Véronique
• Laborde, Lilian
• Castelnau, Olivier

Titel

Prospective Multicenter Validation of the Detection of ALK Rearrangements of Circulating Tumor Cells for Noninvasive Longitudinal Management of Patients With Advanced NSCLC

Ist Teil von

• Journal of thoracic oncology, 2021-05, Vol.16 (5), p.807-816

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Patients with advanced-stage NSCLC whose tumors harbor an ALK gene rearrangement benefit from treatment with multiple ALK inhibitors (ALKi). Approximately 30% of tumor biopsy samples contain insufficient tissue for successful ALK molecular characterization. This study evaluated the added value of analyzing circulating tumor cells (CTCs) as a surrogate to ALK tissue analysis and as a function of the response to ALKi. We conducted a multicenter, prospective observational study (NCT02372448) of 203 patients with stage IIIB/IV NSCLC across nine French centers, of whom 81 were ALK positive (immunohistochemistry or fluorescence in situ hybridization [FISH]) and 122 ALK negative on paraffin-embedded tissue specimens. Blood samples were collected at baseline and at 6 and 12 weeks after ALKi initiation or at disease progression. ALK gene rearrangement was evaluated with CTCs using immunocytochemistry and FISH analysis after enrichment using a filtration method. At baseline, there was a high concordance between the detection of an ALK rearrangement in the tumor tissue and in CTCs as determined by immunocytochemistry (sensitivity, 94.4%; specificity 89.4%). The performance was lower for the FISH analysis (sensitivity, 35.6%; specificity, 56.9%). No significant association between the baseline levels or the dynamic change of CTCs and overall survival (hazard ratio = 0.59, 95% confidence interval: 0.24–1.5, p = 0.244) or progression-free survival (hazard ratio = 0.84, 95% confidence interval: 0.44–1.6, p = 0.591) was observed in the patients with ALK-positive NSCLC. CTCs can be used as a complementary tool to a tissue biopsy for the detection of ALK rearrangements. Longitudinal analyses of CTCs revealed promise for real-time patient monitoring and improved delivery of molecularly guided therapy in this population.